National Health (Listed drugs on F1 or F2) Amendment Determination 2020 (No. 7) (PB 73 of 2020) (Cth)

Case
No judgment structure available for this case.

PB 73 of 2020

National Health (Listed drugs on F1 or F2) Amendment Determination 2020 (No. 7)

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make the following determination.

Dated   30        July 2020  

NIKOLAI TSYGANOV

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments  2

National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010)                 2

1  Name

This instrument is the National Health (Listed drugs on F1 or F2) Amendment Determination 2020 (No. 7).

This instrument may also be cited as PB 73 of 2020.

2  Commencement

(1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1 Column 2 Column 3
Provisions Commencement Date/Details
1.  The whole of this instrument 1 August 2020.

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

This instrument is made under subsection 85AB(1) and section 99AEJ of the National Health Act 1953.

4  Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010)

1  Schedule 1, after item dealing with Entacapone

Insert:

Entrectinib

2Schedule 1, after item dealing with Lithium

Omit “Lurasidone”, substitute “Lorlatinib”.

3Schedule 1, after item dealing with Mepolizumab

Insert:

Mercaptopurine

4  Schedule 1, after item dealing with Nilutamide

Omit “Nitrofurantoin”.

5  Schedule 1, after item dealing with Sterculia with frangula bark

Insert:

Stiripentol

6  Schedule 2, after item dealing with Levodopa with carbidopa

Insert:

Levodopa with carbidopa and entacapone

7  Schedule 2, after item dealing with Losartan

Insert:

Lurasidone

8  Schedule 2, after item dealing with Memantine

Omit “Mercaptopurine”.

9  Schedule 2, after item dealing with Nitrazepam

Insert:

Nitrofurantoin

Actions
Download as PDF Download as Word Document


Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0